Rationale and Design of a Phase II Trial of Dacomitinib in Advanced NSCLC Patients with Uncommon EGFR Mutations

被引：0
|
作者：
Han, B. [1 ]
Zhang, B. [1 ]
Shi, C. [1 ]
Gao, Z. [1 ]
Zhong, H. [1 ]
Xiong, L. [1 ]
Gu, A. [1 ]
Wang, W. [1 ]
Chu, T. [1 ]
Zhang, W. [1 ]
Wang, H. [1 ]
Zhang, X. [1 ]
Zhong, R. [1 ]
机构：
[1] Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Dacomitinib; non-small cell lung cancer; EGFR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.59
引用
收藏
页码：S613 / S613
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of dacomitinib in treatment-naive patients with advanced NSCLC harboring uncommon EGFR mutations
    Wu, L.
    Pu, X.
    Zhou, Y.
    Kong, Y.
    Chen, B.
    Yang, A.
    Li, J.
    Li, K.
    Xu, Y.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1695 - S1695
  • [2] Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Single-Arm, Phase II Multi-Center Trial
    Park, S.
    Ahn, H. K.
    Lee, S.
    Min, Y. J.
    Jung, H. A.
    Sun, J. -M.
    Lee, S-H.
    Ahn, J. S.
    Ahn, M. -J.
    Lee, J. B.
    Kim, S. M.
    Kim, H. R.
    Cho, B. C.
    Hong, M. H.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S148 - S149
  • [3] Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study)
    Bo Zhang
    Chunlei Shi
    Zhiqiang Gao
    Hua Zhong
    Liwen Xiong
    Aiqin Gu
    Weimin Wang
    Tianqing Chu
    Wei Zhang
    Huimin Wang
    Xueyan Zhang
    Runbo Zhong
    Baohui Han
    [J]. BMC Cancer, 22
  • [4] Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study)
    Zhang, Bo
    Shi, Chunlei
    Gao, Zhiqiang
    Zhong, Hua
    Xiong, Liwen
    Gu, Aiqin
    Wang, Weimin
    Chu, Tianqing
    Zhang, Wei
    Wang, Huimin
    Zhang, Xueyan
    Zhong, Runbo
    Han, Baohui
    [J]. BMC CANCER, 2022, 22 (01)
  • [5] Topic: Advanced NSCLC Frequency of Uncommon EGFR Mutations in CR
    Porras Gutierrez, R.
    Corrales-Rodriguez, L.
    Abbas, J.
    Mendez, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1189 - S1189
  • [6] EGFR mutations in patients with advanced NSCLC
    Fiala, Ondrej
    Pesek, Milos
    Finek, Jindrich
    Bruha, Frantisek
    Bortlicek, Zbynek
    Krejci, Jana
    Benesova, Lucie
    Minarik, Marek
    [J]. LUNG CANCER, 2012, 77 : S30 - S30
  • [7] Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC (UNICORN): A phase 2 study
    Okuma, Yusuke
    Kubota, Kaoru
    Shimokawa, Mototsugu
    Hashimoto, Kana
    Kawashima, Yosuke
    Sakamoto, Tomohiro
    Wakui, Hiroshi
    Murakami, Shuji
    Okishio, Kyoichi
    Hayashihara, Kenji
    Ohe, Yuichiro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Clinicopathologic characteristics of NSCLC patients with uncommon EGFR mutations in Korea
    Lee, Yoo Jung
    Yeo, Chang Dong
    Park, Chan Kwon
    Kim, Sung Kyoung
    Kim, Ju Sang
    Kim, Yong Hyun
    Kim, Jin Woo
    Kim, Seung Joon
    Lee, Sang Haak
    Kang, Hye Seon
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [9] Investigation of age and smoking in NSCLC patients with uncommon EGFR mutations
    Maezawa, Yosuke
    Taguchi, Manato
    Kawakami, Takeshi
    Inui, Toshihide
    Okauchi, Shinichiro
    Numata, Takeshi
    Shiozawa, Toshihiro
    Miyazaki, Kunihiko
    Nakamura, Ryota
    Iguchi, Kesato
    Endo, Takeo
    Sakamoto, Tohru
    Satoh, Hiroaki
    Hizawa, Nobuyuki
    [J]. TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2024, 72 (02): : 107 - 113
  • [10] Clinicopathologic characteristics of NSCLC patients with uncommon EGFR mutations in Korea
    Kang, Hye Seon
    Kim, Kyu Yeon
    Lim, Jeong Uk
    Yeo, Chang Dong
    Kim, Ju Sang
    Kim, Seung Joon
    Lee, Sang Haak
    [J]. RESPIROLOGY, 2023, 28 : 100 - 100
12345